CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by BidaskClub

CytomX Therapeutics (NASDAQ:CTMX) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, BidAskClub reports.

Other analysts have also issued research reports about the company. Nomura reaffirmed a “buy” rating and set a $15.00 price objective on shares of CytomX Therapeutics in a research report on Sunday, May 17th. ValuEngine upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. HC Wainwright decreased their price objective on CytomX Therapeutics from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Mizuho reissued a “buy” rating and set a $16.00 price objective on shares of CytomX Therapeutics in a research report on Friday, May 29th. Finally, Zacks Investment Research cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $12.06.

Shares of CTMX opened at $7.01 on Friday. CytomX Therapeutics has a 1 year low of $3.60 and a 1 year high of $15.44. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.77 and a quick ratio of 3.77. The company’s 50-day simple moving average is $8.25 and its 200-day simple moving average is $8.12.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.60. The firm had revenue of $49.59 million during the quarter, compared to analysts’ expectations of $26.93 million. CytomX Therapeutics had a negative net margin of 97.83% and a negative return on equity of 99.72%. As a group, sell-side analysts anticipate that CytomX Therapeutics will post -0.48 earnings per share for the current fiscal year.

In related news, CEO Sean A. Mccarthy sold 36,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $15.00, for a total value of $540,000.00. Following the completion of the transaction, the chief executive officer now directly owns 120,306 shares of the company’s stock, valued at $1,804,590. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.80% of the stock is owned by insiders.

Several large investors have recently modified their holdings of CTMX. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of CytomX Therapeutics by 141.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,922 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 3,469 shares during the last quarter. Meeder Asset Management Inc. lifted its position in CytomX Therapeutics by 133.2% in the first quarter. Meeder Asset Management Inc. now owns 7,941 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 4,536 shares during the last quarter. Diversified Trust Co acquired a new position in CytomX Therapeutics in the second quarter valued at $88,000. Arizona State Retirement System purchased a new position in shares of CytomX Therapeutics during the first quarter worth about $82,000. Finally, Aperio Group LLC purchased a new position in shares of CytomX Therapeutics during the first quarter worth about $83,000. Institutional investors and hedge funds own 78.61% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Featured Story: Fibonacci Channel

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.